Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

World-leading researchers from the UK Pandemic Ethics Accelerator Collaborative consider - how we should evaluate decisions made during the covid-19 pandemic and the future response to pandemic threats.

Professor Ilina Singh, the Ethics Accelerator's Principal Investigator, and PI in the Department of Psychiatry, and Co-Director of the Wellcome Centre for Ethics & Humanities at the University of Oxford, said:

'We are going to have to learn how to live with covid-19. The work of the Ethics Accelerator facilitates grappling with the hard decisions through clear-sighted analysis of what is gained and lost in decisions and choices made individually and collectively. As a society, we all will still need to make trade-offs to suppress the virus in the long term. Those decisions will affect us all. For example, the measures to reduce deaths and protect health services have created risks and impacts elsewhere, including increased waiting list times and people becoming reluctant to seek medical help, as well as impacts on mental health, child development and education.

'In terms of mortality, the pandemic is now forcing us to consider what sorts of deaths, and whose deaths should we be most concerned about, as well as the values that underpin such judgments. Untimely or unexpected deaths are something to be avoided – but at what cost?'

'In considering many of these issues, the approach by government has often been top-down. At the heart of future policies informing the covid-19 recovery must lie serious and genuine attempts to engage a range of perspectives, including the wider public in identifying what is important to them. Understanding how publics judge and respond to risks, and the diverse values that influence these judgments, is crucial in shaping effective and ethical pandemic policy.'

The pandemic has seen not only the tragic deaths caused directly by the virus – 130,000 in the UK and the 3 million worldwide – but also the illness caused by long-covid.

There have been indirect impacts on health too, due to postponed treatments, and to people avoiding health and care systems, leading to delayed diagnosis and treatment. There have also been mental health impacts, resulting from anxiety, loneliness and isolation. We are going to be living with the wider impacts of covid-19 for a long time and we need to consider what priorities and values should guide us through this next phase and into the future.

A series of thought provoking articles has been written, entitled Living and dying with covid:

For more information on the UK Pandemic Ethics Accelerator and to follow on twitter @PandemicEthics_.

Similar stories

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

Improved Risk Estimation of Bipolar Spectrum Disorders in Adolescent Offspring of Bipolar Parents

This new study using Canadian and Swiss data showed that the risk calculator used to predict the likelihood of developing a major mood disorder was correct approximately 70% of the time. The study results suggest this may be a useful clinical tool in routine practice for improved individualised risk estimation of bipolar spectrum disorders among the adolescent offspring of a parent with a bipolar disorder.

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.